Navigation Links
Despite Dramatic Changes, the Crohn's Disease Drug Market Will Experience Only Moderate Growth Through 2019
Date:9/29/2010

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic agents will outpace the decline in sales of older, established agents, which face increasing generics competition and declining use.

The Pharmacor 2010 findings from the topic entitled Crohn's Disease reveal that sales of biologic agents to treat the disease are concentrated as tumor necrosis factor-alpha (TNF-alpha) inhibitors -- namely Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira -- dominated the Crohn's disease market in 2009, capturing just over three-quarters of major-market sales. Owing to increasing physician familiarity with these agents and continuing emergence of favorable postmarketing clinical trial data, sales of TNF-alpha inhibitors will continue to grow, reaching approximately $2.8 billion in 2019.

The Pharmacor 2010 findings also reveal that the 2008 U.S. launches of Biogen Idec/Elan's Tysabri (a cell adhesion molecule inhibitor) and UCB/Otsuka's TNF-alpha inhibitor Cimzia had a negligible impact on the Crohn's disease market. Through 2019, both agents will continue to be relegated to second- or later-line biological therapy, behind Remicade and Humira.

"In 2009, sales of maintenance therapies for Crohn's disease greatly exceeded sales of acute therapies," said Decision Resources Analyst Kathryn Benton. "We expect growth in the market will be largely attributable to increasing sales of maintenance therapies and that sales of acute therapies will remain essentially flat through 2019. However, no current therapy is completely effective in maintaining remission of Crohn's disease and, as a result, significant opportunity remains for more-effective emerging therapies in the maintenance space."

Beginning in 2013, several therapies with novel mechanisms of action are expected to launch for Crohn's disease, including Millennium Pharmaceuticals' vedolizumab, Centocor Ortho Biotech/Janssen-Cilag's Stelara, Abbott's briakinumab and ChemoCentryx/GlaxoSmithKline's Traficet-EN.

"However, we forecast that none of these agents will rival the efficacy or the market share of the TNF-alpha inhibitors," Ms. Benton said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
2. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
3. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
4. UBM Japan Pharma Events Grow Despite Air Travel Disruptions
5. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
6. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
7. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
8. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
11. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):